NASDAQ · Drug Manufacturers - General

Citius Oncology, Inc. (CTOR) Stock

$0.81 -2.61% NASDAQ: CTOR Healthcare

Valuation

MetricValue
Price$0.81
Market Cap$75.61M
P/E Ratio-1.99
P/B Ratio2.54
P/S Ratio12.43
EPS (TTM)$-0.34
52-Week High$2.25
52-Week Low$0.49
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-102.98%
ROA-41.09%
ROCE-88.72%
Gross Margin80.07%
Operating Margin-7.76%
Net Margin-648.32%
Debt/Equity0.25
Current Ratio0.57

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-10.0M$-12.0M$-21.0M$-24.0M
Net Profit$-11.0M$-13.0M$-21.0M$-25.0M
EPS$-0.08$-0.19$-0.30$-0.34
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$43.0M$48.0M$84.0M$101.0M
Total Liabilities$6.0M$22.0M$38.0M$56.0M
Cash$0$0$0$4.0M
Borrowings$0$0$4.0M$4.0M

Latest News

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire · Jul 21, 2026 Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies PR Newswire · Jun 1, 2026 Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR Newswire · May 26, 2026 Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? Insider Monkey · May 24, 2026 Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PR Newswire · May 15, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$0$-1.0M$0$-5.0M
Investing Cash Flow$-67.0M$-1.0M$-5.0M$-6.0M
Financing Cash Flow$0$2.0M$1.0M$0
Net Cash Flow$0$0$0$4.0M
Free Cash Flow$0$-1.0M$0$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-1.90
FCF Yield-22.31%
Quick Ratio0.34
Interest Coverage-86.40
Return 1Y-56.84%
Return 3Y-93.70%
Return 5Y—

Ownership

Insiders Held77.51%
Institutions Held15.32%
Institutions Float Held68.14%
Institutional HolderSharesReport Date
Armistice Capital, LLC9,188,8552026-03-31
Bank of America Corporation3,835,1602026-03-31
Vanguard Capital Management LLC534,8242026-03-31
Geode Capital Management, LLC264,7332026-03-31
Vanguard Fiduciary Trust Co121,9102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $338.46 -0.58% 38.93 $4.97T 0.32%
MSFTMicrosoft Corporation $535.97 +2.56% 28.68 $3.98T 0.76%
GOOGLAlphabet Inc. $351.25 +0.85% 16.94 $4.25T 0.26%
AMZNAmazon.com, Inc. $261.49 +2.92% 19.82 $2.81T 0.00%
METAMeta Platforms, Inc. $719.56 -0.18% 27.93 $1.83T 0.28%

About Citius Oncology, Inc.

Citius Oncology, Inc. is led by CEO Leonard L. Mazur, employs 285 people, headquartered in US, publicly traded since 2022.

Citius Oncology, Inc. (CTOR) stock trades at $0.81 with a market capitalization of $75.61M. The stock is valued at a price-to-earnings (P/E) ratio of -1.99, price-to-book of 2.54, price-to-sales of 12.43. Over the past 52 weeks the stock has ranged between $0.49 and $2.25, and currently trades 64.0% below its 52-week high.

On profitability, Citius Oncology, Inc. generates a return on equity (ROE) of -102.98%, return on capital employed of -88.72%, an operating margin of -7.76%, a net profit margin of -648.32%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1173.15 +0.30% JNJ Johnson & Johnson $260.24 +1.47% ABBV AbbVie Inc. $276.46 +1.48% MRK Merck & Company, Inc. Common Stock (new) $146.28 +2.74% UNH UnitedHealth Group Incorporated Common Stock (DE) $381.63 +2.88% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.30 +0.82% AMGN Amgen Inc. $416.42 +2.20% GILD Gilead Sciences, Inc. $150.73 +2.47% ABT Abbott Laboratories $99.51 +1.04% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides